

# 11 $\beta$ -Hydroxysteroid Dehydrogenase Enzymes Modulate Effects of Glucocorticoids in Rheumatoid Arthritis Synovial Cells

Martin Schmidt<sup>a</sup> Rainer H. Straub<sup>b</sup>

<sup>a</sup>Institute of Biochemistry II, Jena University Hospital, Friedrich Schiller University Jena, Jena, and

<sup>b</sup>Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

## Key Words

Rheumatoid arthritis · Glucocorticoid receptor · 11 $\beta$ -Hydroxysteroid dehydrogenases

## Abstract

The tissue availability of active glucocorticoids (cortisol in humans) depends on their rate of synthesis from cholesterol, downstream metabolism, excretion and interconversion. The latter is mediated by the 11 $\beta$ -hydroxysteroid dehydrogenases (11 $\beta$ HSDs). In this review, we summarize the features of the two isoenzymes, 11 $\beta$ HSD1 and 11 $\beta$ HSD2, and current available experimental data related to 11 $\beta$ HSDs, which are relevant in the context of synovial cells in rheumatoid arthritis (RA). We conclude that due to complex feedback mechanisms inherent to the hypothalamic-pituitary-adrenal axis, currently available transgenic animal models cannot display the full potential otherwise inherent to the techniques. Studies with tissue explants, mixed synovial cell preparations, cell lines derived from synovial cells, and related primary cells or established cell lines indicate that there are relatively clear differences between the two isoenzymes. 11 $\beta$ HSD1 is expressed primarily in fibroblasts and osteoblasts, and may be responsible for fibroblast survival and aid in the resolution of inflammation, but it is also involved in

bone damage. 11 $\beta$ HSD2 is expressed primarily in macrophages and lymphocytes, and may be responsible for their survival, suggesting that it is critical in chronic inflammation. The situation in synovial tissue would allow 11 $\beta$ HSD2-expressing cells to tap the energy resources of 11 $\beta$ HSD1-expressing cells. The overall properties of this local glucocorticoid interconversion system might limit therapeutic use of glucocorticoids in RA.

© 2014 S. Karger AG, Basel

## Introduction

The sheer number of papers (almost 8,000), which can be found in a PubMed search using the search string '(glucocorticoid OR cortisone OR cortisol OR prednisone OR prednisolone OR dexamethasone) AND rheumatoid arthritis', indicate that the introduction of glucocorticoids into the treatment of rheumatoid arthritis (RA) by Hench et al. [1] must be considered a success. In the late 1960s, a role for peripheral cortisone-cortisol interconversion in RA was described [2] and involvement of synovial tissue in this interconversion was shown [3]. However, more detailed elucidation of the underlying mechanisms was possible only after the necessary techniques became available [4].


## 11 $\beta$ -Hydroxysteroid Dehydrogenases

The principle biochemical pathways involved in glucocorticoid synthesis from cholesterol, their interconversion, their downstream metabolism and their excretion are known (fig. 1) and have been described in excellent reviews [5, 6]. It is now evident that the effects of the endogenous glucocorticoids, as well as therapeutic drugs, depend critically on the intra-tissue activities of the enzymes involved in their interconversion, the 11 $\beta$ -hydroxysteroid dehydrogenases (11 $\beta$ HSDs) [7].

In humans, there exist two 11 $\beta$ HSD isoenzymes (EC 1.1.1.146), which are encoded by separate genes and catalyze remarkably different reactions. The type 1 enzyme (11 $\beta$ HSD1) is encoded by the gene HSD11B1 and predominantly mediates the conversion of 11-oxosteroids to their corresponding 11 $\beta$ -hydroxysteroids using NADPH as a cofactor, but might work in a reverse mode under certain circumstances [8, 9]. By contrast, the type 2 enzyme (11 $\beta$ HSD2) is encoded by the gene HSD11B2 and exclusively mediates the conversion of 11 $\beta$ -hydroxysteroids to their corresponding 11-oxosteroids using NAD<sup>+</sup> as a cofactor [10, 11].

Although their most prominent physiological roles are the reactivation of cortisone into the glucocorticoid receptor (GR) agonist cortisol (11 $\beta$ HSD1) and the inactivation of cortisol into the biologically inactive cortisone (11 $\beta$ HSD2), both enzymes can metabolize various additional substrates with similar structures. Generally, these additional substrates are not prominent, but in principle all steroidal substances containing 11-keto/11-hydroxy functional groups can compete with the endogenous corticosteroids for the catalytically active sites of the 11 $\beta$ HSDs [12]. Among these are prednisone or prednisolone, as well as some 7-keto/7-hydroxy cholesterol metabolites, which are sterically similar to normal 11 $\beta$ HSD substrates [9, 13]. Moreover, these metabolites can compete with glucocorticoids for the 11 $\beta$ HSDs active sites [14], which may result in alterations of net conversion rates of cortisol and cortisone, respectively, strongly depending on the concentrations of alternative substrates within a given tissue.

In line with their opposing catalytic activities, expression of both 11 $\beta$ HSD isoenzymes seems to follow simple rules. 11 $\beta$ HSD1 expression levels are highest in tissues where the GR signaling is important, e.g. in the liver [7, 8]. In contrast, 11 $\beta$ HSD2 expression is strong in tissues in which either GR activation should be avoided or glucocorticoids would interfere with specific mineralocorticoid signaling, e.g. in the kidney [7, 10, 11, 15]. This dual function of 11 $\beta$ HSD2 was shown in detail in a study in




**Fig. 1.** Pathways involved in glucocorticoid metabolism. Glucocorticoid synthesis from cholesterol, downstream metabolism and excretion are summarized by arrows. The reactions catalyzed by the two 11 $\beta$ HSD isoforms are shown. The dashed arrow indicates the backward reaction seen only for purified 11 $\beta$ HSD1 in vitro.

human fetal tissues by Condon et al. [16]. In addition, overexpression of 11 $\beta$ HSD2 in pituitary tumors was shown to be at least in part responsible for cell proliferation [17].

### Lessons Learned and Not (Yet) Learned from Animal Models

Transgenic animal models can yield valuable information to elucidate the roles of individual genes or proteins. Accordingly, available mice with targeted inactivation (knock-out) of 11 $\beta$ HSDs were soon analyzed for phenotypic alterations related to inflammatory diseases [reviewed in 18]: mice without 11 $\beta$ HSD1 exhibit a complex but subtle inflammatory phenotype. More recently, it was shown that lack of 11 $\beta$ HSD1 exaggerates inflammation in various mouse models of experimental arthritis [19]. In a rat arthritis model, inhibition of local glucocorticoid reactivation by 11 $\beta$ HSD1, as well as inhibition of GR signaling by RU486, increased inflammatory paw volume (as

**Fig. 2.**  $11\beta$ HSDs modulate the amount of cortisol and its effects. The amount of cortisol (the active glucocorticoid) depends on the functional HPA axis and the activities of the two  $11\beta$ HSD isoenzymes:  $11\beta$ HSD1 increases cortisol and  $11\beta$ HSD2 reduces cortisol; too much cortisol inhibits the HPA axis and reduces the anti-inflammatory androgens. This becomes critical in cells not responding to cortisol because of  $11\beta$ HSD2 expression. Arrows indicate synthesis, induction or activation; blunted lines indicate degradation or inhibition.



readout for inflammation) [20]. But generally the phenotypes seen in these experiments are associated with adrenal hyperplasia and elevated systemic corticosterone levels (the active glucocorticoid in rodents), which seem to compensate for the absence of local reactivation of glucocorticoids by  $11\beta$ HSD1.

This is mirrored in humans, in whom reduced  $11\beta$ HSD1 activity caused by various genetic defects leading to lower locally available concentrations of cortisol (with or without significant changes of cortisol concentrations in the circulation) alter the hypothalamic-pituitary-adrenal (HPA) axis towards hyperandrogenism [6, 21]. This implies that presumably all experimental approaches using systemic manipulation of  $11\beta$ HSD1 activity (both, transgenic and pharmacological) may trigger interfering systemic responses, i.e. dysregulation of the HPA axis and alterations of the ratio of glucocorticoids versus adrenal androgens (fig. 2). Adrenal androgens themselves and their metabolites are important modulators of inflammation in RA, as reviewed previously [22].

From transgenic animal studies, much less evidence exists concerning the role of  $11\beta$ HSD2 in arthritis. No clear effects were seen in the initial studies [18]. More recently, transgenic overexpression of  $11\beta$ HSD2 in osteoblasts was used to reduce the local glucocorticoid signaling. Indeed, it inhibited bone loss in the inflammatory model of K/BxN mouse serum-induced arthritis that usually leads to bone resorption, as demonstrated in the wild-type controls [23]. Moreover, this cell type-restricted alteration of glucocorticoid interconversion reduced local inflammatory activity, most likely via changes in the local levels of pro- and/or anti-inflammatory cytokines.

Taken together, notwithstanding the conclusiveness transgenic animal approaches can provide, results with


these models alone cannot at present clarify the exact roles of the two  $11\beta$ HSDs in arthritis synovial cells. There obviously is a need for more mouse models with cell type-specific knock-out (or overexpression) of  $11\beta$ HSDs to delineate clearly the effects of each isoenzyme on glucocorticoid signaling in individual cell types and the systemic implications thereof – via paracrine or (neuro)endocrine (feedback) mechanisms [21, 24].

### Studies Involving Synovial Cells and Related Specific Cell Types

In recent years, a solid body of evidence from more ‘classical’ experimental approaches appeared for the elucidation of  $11\beta$ HSD-mediated modulation of glucocorticoid signaling in synovial cells. Three types of cell preparations are used in most of the functional studies mentioned: (1) tissue explants, homogenates or freshly isolated mixed synovial cells – which may best represent the *in vivo* mRNA expression, enzyme activities or metabolite concentrations, but lack resolution as to the cell types responsible; (2) cells propagated *in vitro* from synovial cell preparations – mostly synovial fibroblasts, which can be expanded and cultured for a long time, or (3) cell types that are found in RA synovial tissue but are more easily accessible from other sources, e.g. from blood or bone, etc.

As with the animal studies, more knowledge has accumulated concerning the function of  $11\beta$ HSD1 than  $11\beta$ HSD2. Cooper et al. [25] found in an osteosarcoma cell line and in primary osteoblasts that interleukin (IL)-1 $\beta$  or tumor necrosis factor (TNF)- $\alpha$  induced  $11\beta$ HSD1 gene expression and activity, which increased glucocorticoid sensitivity of the cells. Expression of  $11\beta$ HSD1 in tissue sec-

**Fig. 3.** Energy transfer by synovial glucocorticoid metabolism.  $11\beta$ HSD2-expressing cells can generate NADH/H<sup>+</sup> from oxidation of cortisol, which can be further used in oxidative phosphorylation (OXPHOS) to provide ATP. Glucocorticoids are the diffusible intermediates.  $11\beta$ HSD1 regenerates cortisol using NADPH/H<sup>+</sup>, which is generated by the essential enzyme hexose-6-phosphate dehydrogenase (H6PD).



tions from patients with osteoarthritis (OA) and RA was found in the lining and sublining area by immunohistochemistry, and  $11\beta$ HSD1 expression co-localized with the macrophage marker CD163 in double immunofluorescence [26]. Indeed,  $11\beta$ HSD1 is induced in human monocytes upon differentiation to macrophages [27].  $11\beta$ HSD1 expression was induced by the anti-inflammatory IL-10 in synovial macrophages from control patients, but not in macrophages from RA patients [28]. In addition, CD163<sup>-</sup> cells, typically activated macrophages, but not CD3<sup>+</sup> lymphocytes or prolyl 4-hydroxylase-positive fibroblasts, expressed  $11\beta$ HSD1 [26]. However, the enzyme is also expressed in CD90<sup>+</sup> fibroblasts from OA and RA patients [29], which might suggest that there are two subpopulations of synovial fibroblasts. In this study, IL-1 $\beta$  or TNF- $\alpha$  induced expression of  $11\beta$ HSD1 and re-activation of cortisone by  $11\beta$ HSD1 inhibited IL-6 production. Glucocorticoids also induce expression of  $11\beta$ HSD1 and act synergistically with IL-1 $\beta$  or TNF- $\alpha$  in synovial fibroblasts and osteoblasts [30]. Cytokine-mediated induction of  $11\beta$ HSD1 involves NF- $\kappa$ B signaling [31] and is necessary for secretion of a Wnt-antagonist by synovial fibroblasts [32].

Together with the cytokine signaling inhibitor studies in rats [20] and the knock-out mice work [19], a picture emerges in which initiation of inflammation by IL-1 $\beta$ /TNF- $\alpha$  prepares (sensitizes) synovial fibroblasts via expression of  $11\beta$ HSD1 for the anti-inflammatory activity of glucocorticoids. This should contribute to resolution of local inflammation [4].

$11\beta$ HSD2 entered the field of RA quietly, as it was found to be among 9 genes (from 4,300 analyzed) that were upregulated in peripheral blood mononuclear cells from patients with recent-onset RA at least 3-fold compared to healthy individuals [33]. In synovial tissue of patients with RA and OA who underwent knee replacement surgery, we found expression of  $11\beta$ HSD2 in CD163<sup>+</sup> macrophages and CD163<sup>-</sup> cells by double immunofluorescence label-

ing [26]. In this study, the ratio of cells positive for  $11\beta$ HSD2 versus cells positive for  $11\beta$ HSD1 was higher in RA than in OA, and biochemical analysis had shown that in RA the reactivation of cortisone to cortisol is impaired.

A subsequent study using samples from various anatomical sites indicated  $11\beta$ HSD2 expression in synovial macrophages but a net reduction of cortisone [34]. An additional cell type of interest was found to express  $11\beta$ HSD2: in lymphoblastoid B cell lines from RA-discordant twins,  $11\beta$ HSD2 was the second most overexpressed gene in RA cases. Protein expression in synovial tissue of patients was correlated significantly with an inflammation score, suggesting a link between expression of  $11\beta$ HSD2 and the degree of inflammation [35]. Interestingly, a similar link was also found for  $11\beta$ HSD1 activity and levels of erythrocyte sedimentation rate [34].

### The Inflamed Synovium – A Place for Two $11\beta$ HSDs

Thus, both  $11\beta$ HSDs seem to be upregulated in RA (and possibly even in OA, when compared to non-inflamed tissue), albeit in different cell types.  $11\beta$ HSD1 is most prominent in fibroblasts and osteoblasts, whereas  $11\beta$ HSD2 is more prominent in macrophages and B cells (fig. 2).  $11\beta$ HSD2 is not found in mouse macrophages during acute inflammation [36]. It is not expressed during differentiation of isolated human monocytes to macrophages, but it is found in the THP-1 macrophage cell line [27], consistent with the finding of an association of  $11\beta$ HSD2 with cell proliferation [17]. In addition,  $11\beta$ HSD2 expression was downregulated in osteoblasts upon treatment with IL-1 $\beta$  or TNF- $\alpha$  [25]. In combination, available experimental data suggest that  $11\beta$ HSD2 is expressed: (1) in chronic inflammation, (2) in cells from the leukocyte lineage and (3) in cells that presumably seek to avoid glucocorticoid-induced apoptosis (fig. 2). The

last appears to be quite reasonable, as glucocorticoids induce apoptosis in monocytes and macrophages, etc., but prevent apoptosis in other cells, such as fibroblasts [37].

However, there might be another pathway by which 11 $\beta$ HSD2 and glucocorticoids could provide an advantage to a cell surrounded by a growing fibroblast population: 11 $\beta$ HSD2 would allow a cell to tap the biosynthetic/energy resources of adjacent cells based on the shuttling of the diffusible glucocorticoids. Fibroblasts (or osteoblasts) reduce cortisone to cortisol, a reaction driven by their fuels. On the other side, a cortisol-avoiding macrophage or lymphocyte will inactivate cortisol in order to avoid apoptosis and gain some additional NADH/H<sup>+</sup>, which can be further used in oxidative phosphorylation to provide ATP (fig. 3). That would provide a small but almost effortless energy income for macrophages/lymphocytes at the expense of fibroblasts.

## Conclusions

The characteristics of the 11 $\beta$ HSDs explain the tight-rope walk of glucocorticoid therapy for RA and, possibly, other chronic inflammatory diseases. Inhibition of 11 $\beta$ HSD1 may protect bone at the price of hindering resolution of inflammation. Inhibition of 11 $\beta$ HSD2 is accompanied by mineralocorticoid-like side effects, as does application of glucocorticoids in high doses. However, dosage should be high enough to hit the sensitive cells (and/or started before the 11 $\beta$ HSD2 even starts working in the synovial tissue). Combination therapies with biologicals (anti-IL-1 $\beta$  or anti-TNF) should reduce the side effects on bone. Either a targeted delivery system or a tool for cell type-specific inhibition of 11 $\beta$ HSD2 expression seems necessary to affect macrophages and lymphocytes optimally.

## References

- 1 Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. *Proc Staff Meet Mayo Clin* 1949;24:181–197.
- 2 Bailey E, Greaves MS, Murphy D, West HF: Corticosteroid metabolism and rheumatoid arthritis. *Ann Rheum Dis* 1966;25:516–524.
- 3 Murphy D, West HF: Catabolism and interconversion of cortisol and cortisone in human synovial tissue in vitro. *Ann Rheum Dis* 1969;28:637–643.
- 4 Hillier SG: Diamonds are forever: the cortisone legacy. *J Endocrinol* 2007;195:1–6.
- 5 Miller WL: Steroidogenic enzymes. *Endocr Dev* 2008;13:1–18.
- 6 Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW, Stewart PM: 11 $\beta$ -Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. *Endocr Rev* 2013;34:525–555.
- 7 Chapman K, Holmes M, Seckl J: 11 $\beta$ -Hydroxysteroid dehydrogenases: intracellular gatekeepers of tissue glucocorticoid action. *Physiol Rev* 2013;93:1139–1206.
- 8 Seckl JR, Walker BR: 11 $\beta$ -Hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. *Trends Endocrinol Metab* 2004;15:418–424.
- 9 Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM: 11 $\beta$ -Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. *Endocr Rev* 2004;25:831–866.
- 10 Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS: Cloning and tissue distribution of the human 11 $\beta$ -hydroxysteroid dehydrogenase type 2 enzyme. *Mol Cell Endocrinol* 1994;105:R11–R17.
- 11 White PC, Agarwal AK, Nunez BS, Giacchetti G, Mantero F, Stewart PM: Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11 $\beta$ -hydroxysteroid dehydrogenase. *Endocr Res* 2000;26:771–780.
- 12 Morris DJ, Latif SA, Hardy MP, Brem AS: Endogenous inhibitors (GALFs) of 11 $\beta$ -hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. *J Steroid Biochem Mol Biol* 2007;104:161–168.
- 13 Balazs Z, Nashev LG, Chandsawangbhuwana C, Baker ME, Odermatt A: Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11 $\beta$ -hydroxysteroid dehydrogenase 1. *Mol Cell Endocrinol* 2009;301:117–122.
- 14 Mitic T, Shave S, Semjonous N, McNae I, Cobice DF, Lavery GG, Webster SP, Hadoke PW, Walker BR, Andrew R: 11 $\beta$ -Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxyoxysterols in vivo. *Biochem Pharmacol* 2013;86:146–153.
- 15 Odermatt A, Kratschmar DV: Tissue-specific modulation of mineralocorticoid receptor function by 11 $\beta$ -hydroxysteroid dehydrogenases: an overview. *Mol Cell Endocrinol* 2012;350:168–186.
- 16 Condon J, Gosden C, Gardener D, Nickson P, Hewison M, Howie AJ, Stewart PM: Expression of type 2 11 $\beta$ -hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. *J Clin Endocrinol Metab* 1998;83:4490–4497.
- 17 Rabbitt EH, Ayuk J, Boelaert K, Sheppard MC, Hewison M, Stewart PM, Gittoes NJ: Abnormal expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. *Oncogene* 2003;22:1663–1667.
- 18 Holmes MC, Kotelevtsev Y, Mullins JJ, Seckl JR: Phenotypic analysis of mice bearing targeted deletions of 11 $\beta$ -hydroxysteroid dehydrogenases 1 and 2 genes. *Mol Cell Endocrinol* 2001;171:15–20.
- 19 Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE: 11 $\beta$ -Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. *Endocrinology* 2012;153:234–240.
- 20 Ergang P, Leden P, Vagnerova K, Klusonova P, Miksik I, Jurcovicova J, Kment M, Pacha J: Local metabolism of glucocorticoids and its role in rat adjuvant arthritis. *Mol Cell Endocrinol* 2010;323:155–160.
- 21 Cooper MS, Stewart PM: 11 $\beta$ -Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. *J Clin Endocrinol Metab* 2009;94:4645–4654.
- 22 Schmidt M, Naumann H, Weidler C, Schellenberg M, Anders S, Straub RH: Inflammation and sex hormone metabolism. *Ann NY Acad Sci* 2006;1069:236–246.

- 23 Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, Straub RH, Modzelewski J, Dunstan CR, Seibel MJ: Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. *Arthritis Rheum* 2009;60:1998–2007.
- 24 Edwards C: Sixty years after Hench: corticosteroids and chronic inflammatory disease. *J Clin Endocrinol Metab* 2012;97:1443–1451.
- 25 Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM: Modulation of 11 $\beta$ -hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. *J Bone Miner Res* 2001;16:1037–1044.
- 26 Schmidt M, Weidler C, Naumann H, Anders S, Scholmerich J, Straub RH: Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? *Arthritis Rheum* 2005;52:1711–1720.
- 27 Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A: 11 $\beta$ -hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. *J Immunol* 2001;167:30–35.
- 28 Antoniv TT, Ivashkiv LB: Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. *Arthritis Rheum* 2006;54:2711–2721.
- 29 Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M: Differential expression, function and response to inflammatory stimuli of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. *Arthritis Res Ther* 2006;8:R108.
- 30 Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A, Thomas AM, Raza K, Buckley CD, Stewart PM, Rabbitt EH, Hewison M, Cooper MS: Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation-associated bone loss. *Ann Rheum Dis* 2010;69:1185–1190.
- 31 Ahasan MM, Hardy R, Jones C, Kaur K, Nannus D, Juarez M, Morgan SA, Hassan-Smith Z, Benezech C, Caamano JH, Hewison M, Lavery G, Rabbitt EH, Clark AR, Filer A, Buckley CD, Raza K, Stewart PM, Cooper MS: Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. *Arthritis Rheum* 2012;64:2404–2413.
- 32 Hardy R, Juarez M, Naylor A, Tu J, Rabbitt EH, Filer A, Stewart PM, Buckley CD, Raza K, Cooper MS: Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis. *Arthritis Res Ther* 2012;14:R226.
- 33 Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, Aune TM: A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. *Ann Rheum Dis* 2004;63:1387–1392.
- 34 Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes NJ, Buckley CD, Raza K, Cooper MS: Local and systemic glucocorticoid metabolism in inflammatory arthritis. *Ann Rheum Dis* 2008;67:1204–1210.
- 35 Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, Ling S, Chinnaiyan AM, Holoshitz J: Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. *Arthritis Rheum* 2006;54:2047–2060.
- 36 Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR: Local amplification of glucocorticoids by 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. *Ann NY Acad Sci* 2006;1088:265–273.
- 37 Viegas LR, Hoijman E, Beato M, Pecci A: Mechanisms involved in tissue-specific apoptosis regulated by glucocorticoids. *J Steroid Biochem Mol Biol* 2008;109:273–278.